This document provides an overview of survival analysis concepts and methods. It defines time-to-event data and censoring, and describes how to calculate a Kaplan-Meier survival curve from censored data. It also discusses log-rank tests to compare survival curves between groups and the Cox proportional hazards regression model for assessing the effects of multiple covariates on survival.
Introduction to survival analysis Providing intuition of hazard function, survival function, cumulative failure function. Life table, KM and log-rank test
Introduction to survival analysis Providing intuition of hazard function, survival function, cumulative failure function. Life table, KM and log-rank test
5 essential steps for sample size determination in clinical trials slidesharenQuery
In this free webinar hosted by nQuery Researcher & Statistician Eimear Keyes, we map out the 5 essential steps for sample size determination in clinical trials. At each step, Eimear will highlight the important function it plays and how to avoid the errors that will negatively impact your sample size determination and therefore your study.
Watch the Video: https://www.statsols.com/webinar/the-5-essential-steps-for-sample-size-determination
Multiple Regression and Logistic RegressionKaushik Rajan
1) Multiple Regression to predict Life Expectancy using independent variables Lifeexpectancymale, Lifeexpectancyfemale, Adultswhosmoke, Bingedrinkingadults, Healthyeatingadults and Physicallyactiveadults.
2) Binomial Logistic Regression to predict the Gender (0 - Male, 1 - Female) with the help of independent variables such as LifeExpectancy, Smokingadults, DrinkingAdults, Physicallyactiveadults and Healthyeatingadults.
Tools used:
> RStudio for Data pre-processing and exploratory data analysis
> SPSS for building the models
> LATEX for documentation
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...Waqas Tariq
The Kaplan Meier method is used to analyze data based on the survival time. In this paper used Kaplan Meier procedure and Cox regression with these objectives. The objectives are finding the percentage of survival at any time of interest, comparing the survival time of two studied groups and examining the effect of continuous covariates with the relationship between an event and possible explanatory variables. The variables (Age, Gender, Weight, Drinking, Smoking, District, Employer, Blood Group) are used to study the survival patients with cancer stomach. The data in this study taken from Hiwa/Hospital in Sualamaniyah governorate during the period of (48) months starting from (1/1/2010) to (31/12/2013) .After Appling the Cox model and achieve the hypothesis we estimated the parameters of the model by using (Partial Likelihood) method and then test the variables by using (Wald test) the result show that the variables age and weight are influential at the survival of time.
5 essential steps for sample size determination in clinical trials slidesharenQuery
In this free webinar hosted by nQuery Researcher & Statistician Eimear Keyes, we map out the 5 essential steps for sample size determination in clinical trials. At each step, Eimear will highlight the important function it plays and how to avoid the errors that will negatively impact your sample size determination and therefore your study.
Watch the Video: https://www.statsols.com/webinar/the-5-essential-steps-for-sample-size-determination
Multiple Regression and Logistic RegressionKaushik Rajan
1) Multiple Regression to predict Life Expectancy using independent variables Lifeexpectancymale, Lifeexpectancyfemale, Adultswhosmoke, Bingedrinkingadults, Healthyeatingadults and Physicallyactiveadults.
2) Binomial Logistic Regression to predict the Gender (0 - Male, 1 - Female) with the help of independent variables such as LifeExpectancy, Smokingadults, DrinkingAdults, Physicallyactiveadults and Healthyeatingadults.
Tools used:
> RStudio for Data pre-processing and exploratory data analysis
> SPSS for building the models
> LATEX for documentation
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...Waqas Tariq
The Kaplan Meier method is used to analyze data based on the survival time. In this paper used Kaplan Meier procedure and Cox regression with these objectives. The objectives are finding the percentage of survival at any time of interest, comparing the survival time of two studied groups and examining the effect of continuous covariates with the relationship between an event and possible explanatory variables. The variables (Age, Gender, Weight, Drinking, Smoking, District, Employer, Blood Group) are used to study the survival patients with cancer stomach. The data in this study taken from Hiwa/Hospital in Sualamaniyah governorate during the period of (48) months starting from (1/1/2010) to (31/12/2013) .After Appling the Cox model and achieve the hypothesis we estimated the parameters of the model by using (Partial Likelihood) method and then test the variables by using (Wald test) the result show that the variables age and weight are influential at the survival of time.
El paquete TestSurvRec implementa las pruebas estadíıticas para comparar dos curvas de supervivencia con eventos recurrentes. Este software ofrece herramientas ´utiles para el an´alisis de la supervivencia en el campo de la biomedicina, epidemiolog´ıa, farmac´eutica y otras áreas. El paquete TestSurvRec contiene dos conjuntos de datos con eventos recurrentes, un conjunto de datos referido al experimento de Byar que contiene los tiempos de recurrencia de tumores de c´ancer de vejiga en los pacientes tratados con piridoxina, tiotepa o considerado como un placebo. Y otro conjunto de datos que contiene los tiempos de rehospitalizaci´on despu´es de la cirug´ıa en pacientes con cáncer colorrectal. Estos datos provienen de un estudio que se llev´o a cabo en el Hospital de Bellvitge, un hospital universitario p´ublico en Barcelona (España).
Large amounts of heterogeneous medical data have become available in various healthcare organizations (payers, providers, pharmaceuticals). Those data could be an enabling resource for deriving insights for improving care delivery and reducing waste. The enormity and complexity of these datasets present great challenges in analyses and subsequent applications to a practical clinical environment. More details are available here http://dmkd.cs.wayne.edu/TUTORIAL/Healthcare/
Este manual es útil e indispensable para el uso del "Package TesSurvRec_1.2.1" de CRAN. Importante para estadístico, médicos, farmacéuticos, seguros, bancos, ingenieros, psicólogos, astrónomos, entre otras profesiones. Son pruebas estadísticas que se utilizan para medir diferencias entre funciones del análisis de supervivencias de grupos de poblaciones que manifiestan eventos recurrentes.
Chapter 11
Survival Analysis
Learning Objectives
• Identify applications with time to event
outcomes
• Construct a life table using the actuarial
approach
• Construct a life table using the Kaplan-Meier
approach
Learning Objectives
• Perform and interpret the log-rank test
• Compute and interpret a hazard ratio
• Interpret regression coefficients in a Cox
proportional hazards regression analysis
Survival Analysis
• Outcome is time to event
– Time to heart attack, cancer remission, death
• Measure whether person has event or not
(Yes/No) and Time to event
• Estimate “survival time”
• Determine factors associated with longer
survival
Issues with Time to Event Data
• Times are positive (often skewed)
• Incomplete follow-up information
– Some participants enroll late
– Some participants drop-out
– Study ends
• Censoring
– Measure follow-up time and not time to event
– We know survival time > follow-up time
Experiences of n=10 Participants
Experiences of Same n=10 Participants, Time
Projected to Zero
Is the Following Different?
Survival Curve – Survival Function
Survival Curve with 95% CI
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 5 10 15 20 25
Time, Years
S
ur
vi
va
l
P
ro
ba
bi
li
ty
Estimating the Survival Function
• There are many parametric approaches (which
make certain assumptions about survival
times)
• We focus on two non-parametric approaches
– Actuarial or life table approach
– Kaplan-Meier approach
Example 11.2.
Estimating the Survival Function
• Participants are 65 years and older, followed
for up to 24 years until the die, until the study
ends or until they drop out.
• n=20 participants are enrolled over a 5 year
period.
Example 11.2.
Estimating the Survival Function
Year of Death or Year of Last Contact
• Years of Death: 3, 14, 1, 23, 5, 17
• Years of Last Contact: 24, 11, 19, 24, 13, 2,
18, 17, 24, 21, 12, 10, 6, 9
Notation
Nt = number of participants who are event free and
considered at risk during interval
Dt = number who suffer event during interval
Ct = number censored during interval
qt = proportion suffering event during interval
pt = proportion surviving interval
St = proportion surviving past interval
Example 11.2. Life Table
Example 11.2.
Life Table – Actuarial Approach
Example 11.2. Life Table – Kaplan-Meier Approach
Example 11.2 Survival Function
Comparing Survival Curves
• Log rank test to compare survival in two or
more independent groups
• Chi-square test that compares the observed
numbers of events to what would be expected
if the groups had equal survival
Example 11.3.
Comparing Survival
• Clinical trial to compare two treatments for advanced
gastric cancer
• n=20 participants with stage IV cancer are randomly
assigned to receive chemotherapy before surgery or
chemotherapy after surgery
• Primary outcome is death
• Participants are followed for up to 48 ...
I am Luke M. I love exploring new topics. Academic writing seemed an interesting option for me. After working for many years with statisticsassignmentexperts.com. I have assisted many students with their assignments. I can proudly say, each student I have served is happy with the quality of the solution that I have provided. I have acquired my Master’s Degree in Statistics, from Arizona University, United States.
Answer the following. (5 pts ea)A study is conducted to estimate.docxboyfieldhouse
Answer the following. (5 pts ea)
A study is conducted to estimate survival in patients following kidney transplant. Key factors that adversely affect success of the transplant include advanced age and diabetes. This study involves 25 participants who are 65 years of age and older and all have diabetes. Following transplant, each participant is followed for up to 10 years. The following are times to death, in years, or the time to last contact (at which time the participant was known to be alive).
Deaths: 1.2, 2.5, 4.3, 5.6, 6.7, 7.3 and 8.1 years
Alive: 3.4, 4.1, 4.2, 5.7, 5.9, 6.3, 6.4, 6.5, 7.3, 8.2, 8.6, 8.9, 9.4, 9.5, 10, 10, 10, and 10 years
Use the life table approach to estimate the survival function. Use years intervals of
0-2; 2-4;
Complete the table below.
Interval
in
Years
Number At Risk During Interval,
N
t
Average Number At Risk During Interval,
N
t*
=Nt-C
t
/2
Number of Deaths During Interval,
D
t
Lost to Follow-Up,
C
t
Proportion Dying
q
t
= D
t
/N
t*
Proportion Surviving
pt = 1-qt
Survival Probability
S
t
= pt*S
t-1
0-2
2-4
4-6
6-8
8-10
1.
cont.
Use the Kaplan-Meier approach to estimate the survival function.
Complete the table below
Time, Years
Number at Risk
Nt
Number of Deaths
Dt
Number Censored
Ct
Survival Probability
S
t+1
= S
t
*((N
t
-D
t
)/N
t
)
0
25
1.2
2.5
3.4
4.1
4.2
4.3
5.6
5.7
5.9
6.3
6.4
6.5
6.7
7.3
8.1
8.2
8.6
8.9
9.4
9.5
10.0
1.
cont.
Referring to the graph above –
What is the probability of surviving 6.5 years?
A.
None
B.
0.85
C.
0.60
D.
0.90
Patients have an 85% chance of surviving how many years?
A.
6.0
B.
4.25
C.
3.2
D.
5.5
2.
An observational cohort study is conducted to compare time to early failure in patients undergoing joint replacement surgery. Of specific interest is whether there is a difference in time to early failure between patients who are considered obese versus those who are not. The study is run for 40 weeks and times to early joint failure, measured in weeks, are shown below for participants classified as obese or not at the time of surgery.
Obese
Not Obese
Failure
No Failure
Failure
No Failure
28
39
27
37
25
41
31
36
31
37
34
39
32
35
40
38
36
36
32
29
39
41
Estimate the survival functions (time to early joint failure) for each group using the Kaplan-Meier approach.
Complete the table below.
Obese
Time, Weeks
Number at Risk
Nt
Number of Events (Joint Failures)
Dt
Number Censored
Ct
Survival Probability
S
t+1
= S
t
*((N
t
-D
t
)/N
t
)
0
11
25
28
29
31
32
35
36
37
38
39
41
2.
cont.
Non-Obese
Complete the table below.
Time, Weeks
Number at Risk
Nt
Number of Events (Joint Failures)
Dt
Number Censored
Ct
Survival Probability
S
t+1
= S
t
*((N
t
-D
t
)/N
t
)
0
11
27
31
32
34
36
37
39
40
41
To answer t.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
1. Essentials of survival analysis
How to practice evidence based
oncology
European School of Oncology
July 2004
Antwerp, Belgium
Dr. Iztok Hozo
Professor of Mathematics
Indiana University NW
www.iun.edu/~mathiho
2. Time-to-Event
Time-to-event data are generated when the measure of interest is
the amount of time to occurrence of an event of interest.
For Example:
– Time from randomization to death in clinical trial
– Time from randomization to recurrence in a cancer clinical trial
– Time from diagnosis of cancer to death due to the cancer
– Time from diagnosis of cancer to death due to any causes
– Time from remission to relapse of leukemia
– Time from HIV infection to AIDS
– Time from exposure to cancer incidence in an epidemiological
cohort study
3. Censoring
Censoring occurs when we have some information, but we don’t know
the exact time-to-event measure.
For example, patients typically enter a clinical study at the time
randomization (or the time of diagnosis, or treatment) and are followed
up until the event of interest is observed.
However, censoring may occur for the following reasons:
a person does not experience the event before the study ends;
death due to a cause not considered to be the event of interest (traffic
accident, adverse drug reaction,…); and
loss to follow-up, for example, if the person moves.
We say that the survival time is censored. These are examples of right
censoring, which is the most common form of censoring in medical
studies. For these patients, the complete time-to-event measure is
unknown; we only know that the true time-to-event measure is greater
than the observed measurement.
5. Example 2 (from Kleinbaum: “Survival Analysis”)
Patient Time (t) Censor (d)
1 23 1
2 47 1
3 69 1
4 70 0
5 71 0
6 100 0
7 101 0
8 148 1
9 181 1
10 198 0
11 208 0
12 212 0
13 224 0
Consider data from a retrospective
study of 13 women who had surgery
for breast cancer. The survival times
are:
23, 47, 69, 70+, 71+, 100+, 101+,
148, 181, 198+, 208+, 212+, 224+
(the “+” means that that particular patient was
censored)
6. Survival Curve - Calculus
S(t) = cumulative survival function = proportion that survive until time t
f(t) = frequency distribution of age at death
h(t) = hazard function (i.e. death rate at age t) = event rate
Relationships:
t
duuh
t
eduuftTPtS 0
dt
tdS
tf
tS
dt
d
tS
tf
TtPt
ttTtP
t
TtttTtP
th
t
t
lnlim
|
lim
0
0
7. Distribution Function, Survival Function
and Density Function
)(1)Pr()( tFtTtS
Probability Distribution function
Probability Density function
Survival function t
tF
tf
)(
)(
)Pr()( tTtF
8. Creating a Kaplan-Meier curve
j
jj
n
dn
211 | jjj tTtTPt
1
11
1
11
0132
21
|...|
|
n
dn
n
dn
n
dn
tTtTPtTtTP
tTtTPtTPtS
j
jj
j
jj
jj
jj
For each non-censored failure time tj (time-to-event time) evaluate:
•nj = number at risk before time tj
•dj = number of deaths from tj-1 to tj
•Fraction
= estimated probability of surviving past tj-1
given that you are at risk at time
The Product Limit Formula:
9. Kaplan-Meier Product Limit Estimate
Consider data from a retrospective study of 45 women who had surgery for breast cancer. The
survival times are: 23, 47, 69, 70+, 71+, 100+, 101+, 148, 181, 198+, 208+, 212+, 224+
j Interval n j d j S (t)
1 13 0 1.00 1.00
2 13 1 0.92 0.92
3 12 1 0.92 0.85
4 11 1 0.91 0.77
5 6 1 0.83 0.64
6 5 1 0.80 0.51
230 t
4723 t
6947 t
14869 t
181148 t
t181
j
jj
n
dn
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0 20 40 60 80 100 120 140 160 180 200
11. Survival Curves – more examples
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 100 200 300 400 500 600 700 800 900
Days Since Index Hospitalization
Warf
ASA
No Rx
Age 76 Years and Older (N = 394)
12. Log-Rank test for two groups
Suppose we have two groups,
each with a different treatment.
Usually, we represent this kind
of situation in a 2x2 table.
Event No Event
Intervention 45 198
Control 52 203
or
# at Risk # Events
Intervention n1 = 243 m1 = 45
Control n2 = 255 m2 = 52
TOTAL: N = 498 M = 97
Expected number of events:
Intervention 47.33
Control 49.67
Observed- Expected: -2.33
Variance: 19.55
risktotal
eventstotal
groupExpected
__#
__#
#
12
21
NN
MNMnn
Var
ExpectedObservedEO
13. If the data are given through time, we have a series of
2x2 tables.
Expected number of events
If the two groups were the same – what would the
expected number of events be?
Observed minus expected
This is a measure of deviation of one treatment from
their average (the expected)
Log-rank statistic measures whether the data in the two
groups are statistically “different”.
Log-Rank test for two groups
14. Comparing Survival Functions
Question: Did the treatment make a
difference in the survival experience of
the two groups?
Hypothesis: H0: S1(t)=S2(t) for all t ≥ 0.
Three often used tests:
1. Log-rank test (aka Mantel-Haenszel Test);
2. Wilcoxon Test;
3. Likelihood ratio test.
18. Log-Rank test for several groups
The null hypothesis is that all the survival curves are
the same.
Log-rank statistic is given by the sum:
This statistic has Chi-square distribution with (# of
groups – 1) degrees of freedom.
groupsof
i i
ii
groupsof
i ii
ii
E
EO
EOVar
EO
X
__# 2__# 2
2
19. Cox Proportional Hazards Regression
Most interesting survival-analysis research examines the
relationship between survival — typically in the form of the
hazard function — and one or more explanatory variables (or
covariates).
Most common are linear-like models for the log hazard.
For example, a parametric regression model based on the
exponential distribution,
Needed to assess effect of multiple covariates on survival
Cox-proportional hazards is the most commonly used
multivariate survival method
Easy to implement in SPSS, Stata, or SAS
Parametric approaches are an alternative, but they require
stronger assumptions about h(t).
20. Assumes multiplicative risk—this is the proportional hazard
assumption
Conveniently separates baseline hazard function from
covariates
Baseline hazard function over time
Covariates are time independent
Nonparametric
Can handle both continuous and categorical predictor
variables (think: logistic, linear regression)
Without knowing baseline hazard ho(t), can still calculate
coefficients for each covariate, and therefore hazard ratio
Multivariate methods:
Cox proportional hazards
21. Limitations of Cox PH model
Covariates normally do not vary over time
True with respect to gender, ethnicity, or congenital
condition
One can program time-dependent variables
Baseline hazard function, ho(t), is never specified, but
Cox PH models known hazard functions
You can estimate ho(t) accurately if you need to estimate
S(t).
22. Hazard Ratio
Interesting to interpret
For example, if HR = 0.70, we can deduce the following:
Relative effect on survival is
or 30% reduction of the risk of death
Absolute Difference in survival is given as
so, if S = 60%,
which represents a 10% difference.
Difference in median survival is given as the difference between the
median/HR and the median. For example, if the median is
months, then the difference is given as
or 10.71 months increase in median survival.
30.070.011 HR
SSSe HRHRS
ln
10.060.060.0 70.0
AbsDiff
25
71.1025
70.0
25
V
EO
eHR